Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Merck-Simcere China Drug JV Breaking Apart

publication date: Feb 6, 2015
Merck is pulling out of its highly visible China drug JV with Simcere Pharma. In 2011, the two companies announced that each company would contribute some of their own pharmaceutical assets to the JV, which would develop, make and market branded generic drugs. Merck owned a majority 51% stake in the JV, with Simcere claiming the rest. But now Simcere will be in charge of the JV, which is known as SMSD. At the moment, neither company has released details about the JV's future, saying only that changing circumstances forced the parties to rethink the JV's strategy. More details....

Stock Symbol: (NYSE: MRK)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021